Four cancer patients are treated with an experimental drug. Patients #2 and #4 have an extremely serious adverse reaction to the drug. Another patient (#5) requests to enter the trial, and you do not wish to treat this patient if there is any indication that the new patient will have the same side effect. The haplotypes for the region where the allele that controls this sensitivity has been mapped, and the haplotypes for this region for these patients are given below. Should you enter patient #5 into the trial?
1: 1A 2B 3C 4B/1A 2B 3A 4C
2: 1A 2C 3B 4B/1B 2A 3B 4A
3: 1B 2A 3A 4B/1C 2B 3A 4A
4: 1B 2C 3B 4B/1A 2B 3A 4C
5: 1A 2B 3A 4C/1B 2A 3B 4A
a) No, #5 shares the 1A haplotype with #2 and #4.
b) Yes, #5 shares no haplotype combinations with #2 and #4.
c) No, #5 shares the 3B haplotype with #2 and #4.
d) Yes, since there are no shared haplotypes between #2 and #4, these haplotypes are not correlating with the drug sensitivity.